Surgalign Holdings (OTCPK:SRGA.Q) - Stock Price, News & Analysis

Resumen acción SRGA.Q

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide.

Acerca de la empresa

SRGA.Q fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los beneficios han disminuido en 9.6% al año en los últimos 5 años.

No tiene una capitalización bursátil significativa ($165K)

Patrimonio neto negativo

Alta volatilidad del precio de la acción en los últimos 3 meses

+ 2 riesgos adicionales

Competidores de Surgalign Holdings, Inc.

Sientra

OTCPK:SIEN.Q

US$729.4k

InVitro International

OTCPK:IVRO

US$1.2m

Procyon

OTCPK:PCYN

US$1.6m

SmileDirectClub

OTCPK:SDCC.Q

US$1.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Surgalign Holdings
Historical stock prices
Current Share Price	US$0.018
52 Week High	US$4.00
52 Week Low	US$0.005
Beta	1.49
1 Month Change	63.64%
3 Month Change	-80.00%
1 Year Change	-99.50%
3 Year Change	-99.97%
5 Year Change	-99.99%
Change since IPO	-100.00%

Noticias y actualizaciones recientes

Recent updates

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Aug 24

Rentabilidad de los accionistas

	SRGA.Q	US Medical Equipment	Mercado US
7D	16.1%	-2.0%	-1.7%
1Y	-99.5%	3.1%	22.4%

Rentabilidad vs. Industria: SRGA.Q obtuvo unos resultados inferiores a los del sector US Medical Equipment , que el año pasado arrojó un rendimiento del -1.8%.

Rentabilidad vs. Mercado: SRGA.Q obtuvo unos resultados inferiores a los del mercado US, que fue del 15.2% el año pasado.

Volatilidad de los precios

Is SRGA.Q's price volatile compared to industry and market?
SRGA.Q volatility
SRGA.Q Average Weekly Movement	40.5%
Medical Equipment Industry Average Movement	7.5%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: SRGA.Qha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: SRGA.QLa volatilidad semanal ha pasado de 28% a 40% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1997	240	Terry Rich	www.surgalign.com

Resumen de fundamentos de Surgalign Holdings, Inc.

¿Cómo se comparan los beneficios e ingresos de Surgalign Holdings con su capitalización de mercado?
Estadísticas fundamentales de SRGA.Q
Capitalización bursátil	US$165.30k
Beneficios(TTM)	-US$50.49m
Ingresos (TTM)	US$78.12m

0.0x

Ratio precio-ventas (PS)

0.0x

Ratio precio-beneficio (PE)

¿Está SRGA.Q sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de SRGA.Q
Ingresos	US$78.12m
Coste de los ingresos	US$26.03m
Beneficio bruto	US$52.09m
Otros gastos	US$102.58m
Beneficios	-US$50.49m

Últimos beneficios comunicados

Mar 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-5.50
Margen bruto	66.68%
Margen de beneficio neto	-64.63%
Ratio deuda/patrimonio	-54.1%

¿Cómo se ha desempeñado SRGA.Q a largo plazo?

Ver rendimiento histórico y comparativa

Resumen acción SRGA.Q

Recompensas

Análisis de riesgos

Competidores de Surgalign Holdings, Inc.

OTCPK:SIEN.Q

US$729.4k

OTCPK:IVRO

US$1.2m

OTCPK:PCYN

US$1.6m

OTCPK:SDCC.Q

US$1.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Recent updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Consensus revenue estimates fall by 38%

Full year 2022 earnings: EPS misses analyst expectations

Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million.

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System

Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission

Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio

Chief Financial Officer recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System

Price target decreased to US$1.00

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System

Surgalign Holdings - A Future Of Digital Surgery

Price target decreased to US$2.85

Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020)

Sizing Up Surgalign

Independent Director Jeffrey Lightcap has left the company

Chairman Stuart Simpson has left the company

Surgalign Holdings: Insiders Are Buying

Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation

President recently bought US$1.0m worth of stock

Surgalign Holdings: Pinocchio Has A Happy Ending

Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020)

Price target decreased to US$4.21

Surgalign Holdings: A Marketing Ploy

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index

Surgalign reports inducement grants under Nasdaq listing rule

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020)